Randomized phase II study comparing cisplatin plus pemetrexed plus bevacizumab with carboplatin plus paclitaxel plus bevacizumab in treatment-naive advanced non-squamous non-small cell lung cancer (CLEAR study)

被引：0

作者：

Koyama, R. ^{[1
]}

Udagawa, H. ^{[2
]}

Sugiyama, E. ^{[3
]}

Komuta, K. ^{[4
]}

Mori, M. ^{[5
]}

Yokoyama, T. ^{[6
]}

Sasaki, T. ^{[7
]}

Saito, H. ^{[8
]}

Ishida, H. ^{[9
]}

Nakagawa, H. ^{[10
]}

Sekine, A. ^{[11
]}

Tamura, A. ^{[12
]}

Shingyoji, M. ^{[13
]}

Mizuno, K. ^{[14
]}

Nakamura, A. ^{[15
]}

Kinoshita, A. ^{[16
]}

Yamanaka, T. ^{[17
]}

Goto, K. ^{[2
]}

机构：

[1] Juntendo Univ, Fac Med, Dept Resp Med, Tokyo, Japan

[2] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan

[3] Natl Canc Ctr, Div Canc Immunol, Kashiwa, Chiba, Japan

[4] Osaka Police Hosp, Dept Resp Med, Osaka, Japan

[5] Natl Hosp Org Toneyama Natl Hosp, Dept Thorac Oncol, Toyonaka, Osaka, Japan

[6] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan

[7] Asahikawa Med Univ, Resp Ctr, Asahikawa, Hokkaido, Japan

[8] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan

[9] Showa Univ, Div Med Oncol, Sch Med, Tokyo, Japan

[10] Natl Hosp Org Hirosaki Hosp, Dept Resp Med, Hirosaki, Aomori, Japan

[11] Kanagawa Cardiovasc & Resp Ctr, Dept Resp Med, Yokohama, Kanagawa, Japan

[12] Natl Hosp Org Tokyo Natl Hosp, Ctr Pulm Dis, Tokyo, Japan

[13] Chiba Canc Ctr, Div Respirol, Chiba, Japan

[14] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Pulm Med, Kagoshima, Japan

[15] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan

[16] Nagasaki Prefecture Shimabara Hosp, Dept Resp Med, Shimabara, Japan

[17] Yokohama City Univ Med, Dept Biostat, Yokohama, Kanagawa, Japan

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1436P

引用

页数：1

共 50 条

[21] AN INDIRECT COMPARISON OF THE EFFICACY OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) OR BEVACIZUMAB PLUS CARBOPLATIN AND PACLITAXEL (BCP) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
Walzer, S.
de Castro Carpeno, J.
Vergnenegre, A.
Chouaid, C.
Heigener, D.
Bischoff, H. G.
Aultman, R.
Siebert, U.
[J]. VALUE IN HEALTH, 2009, 12 (07) : A258 - A258
[22] Prospective phase II study of cisplatin plus pemetrexed with maintenance of pemetrexed for advanced non-squamous cell non-small cell lung cancer in Japan
Asami, Kazuhiro
Kawahara, Masaaki
Hirashima, Tomonori
Suzuki, Hidekazu
Okishio, Kyoichi
Omachi, Naoki
Tamiya, Motohiro
Tamiya, Akihiro
Hirooka, Aya
Nakao, Keiko
Tsuji, Taisuke
Atagi, Shinji
[J]. THORACIC CANCER, 2014, 5 (04) : 289 - 296
[23] Randomized phase II study of pemetrexed plus carboplatin followed by pemetrexed versus paclitaxel plus carboplatin followed by pemetrexed in advanced nonsquamous, non-small cell lung cancer (LOGIK 0904)
Takayama, Koichi
Inoue, Koji
Takeshita, Masafumi
Tashiro, Naoki
Harada, Taishi
Seto, Takashi
Imanaga, Tomotoshi
Fujimoto, Noriko
Nakagaki, Noriaki
Kawasaki, Masayuki
Kishimoto, Junji
Ichinose, Yukito
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[24] A phase II study of metformin plus pemetrexed and carboplatin in patients with non-squamous non-small cell lung cancer (METALUNG)
S. Verma
S. Chitikela
V. Singh
S. Khurana
D. Pushpam
D. Jain
S. Kumar
Y. Gupta
P. S. Malik
[J]. Medical Oncology, 40
[25] A phase II study of metformin plus pemetrexed and carboplatin in patients with non-squamous non-small cell lung cancer (METALUNG)
Verma, S.
Chitikela, S.
Singh, V.
Khurana, S.
Pushpam, D.
Jain, D.
Kumar, S.
Gupta, Y.
Malik, P. S.
[J]. MEDICAL ONCOLOGY, 2023, 40 (07)
[26] Anlotinib plus carboplatin/pemetrexed in treatment-naive advanced non-squamous NSCLC: An open-label, randomized, phase II study
Guo, R.
Gao, W.
Li, J.
Liu, Y.
Liu, X.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S801 - S801
[27] A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naive Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
Marrone, Kristen A.
Zhou, Xian
Forde, Patrick M.
Purtell, Michael
Brahmer, Julie R.
Hann, Christine L.
Kelly, Ronan J.
Coleman, Barbara
Gabrielson, Edward
Rosner, Gary L.
Ettinger, David S.
[J]. ONCOLOGIST, 2018, 23 (07): : 859 - 865
[28] Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclitaxel for non‐squamous non‐small cell lung cancer with malignant pleural effusion
Motohiro Tamiya
Akihiro Tamiya
Hidekazu Suzuki
Yoshihiko Taniguchi
Kanako Katayama
Shojiro Minomo
Keiko Nakao
Naoko Takeuchi
Yoshinobu Matsuda
Yujiro Naito
Takayuki Shiroyama
Norio Okamoto
Kyoichi Okishio
Toru Kumagai
Shinji Atagi
Fumio Imamura
Tomonori Hirashima
[J]. Investigational New Drugs, 2021, 39 : 1106 - 1112
[29] PHASE II STUDY OF PEMETREXED plus CARBOPLATIN plus BEVACIZUMAB AS FIRST LINE THERAPY FOR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION: CENTRAL JAPAN LUNG STUDY GROUP (CJLSG) 0910 TRIAL
Kimura, Tomoki
Taniguchi, Hiroyuki
Ogasawara, Tomohiko
Suzuki, Ryujiro
Kondo, Masashi
Shindoh, Joe
Yoshida, Norio
Kojima, Eiji
Yamada, Yoshiyuki
Hataji, Osamu
Ichikawa, Motoshi
Saito, Hiroshi
[J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1167 - S1167
[30] A phase III, open-label, randomized study of atezolizumab in combination with carboplatin plus paclitaxel plus bevacizumab compared with pemetrexed plus cisplatin or carboplatin with stage IV non-squamous non-small cell lung cancer (NSCLC) with activating EGFR mutation or ALK translocation (ATLAS Trial).
Park, Sehhoon
Lee, Yun-Gyoo
Park, Ji Hyun
Lee, Gyeong-Won
Kang, Eun Joo
Choi, Yoon Ji
Shin, SeongHoon
Han, Ji-Youn
Lee, Suee
Kim, YuJung
Kim, Tae Min
Kim, Sang-We
Shim, Byoung Yong
Cho, Jinhyun
Kim, Hye Sook
Park, Sang Gon
Lee, Ki Hyeong
Kim, Ilhwan
Ahn, Myung-Ju
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →